MicuRx Pharmaceuticals Gets $55M For Antibiotics Development
Hayward-based MicuRx Pharmaceuticals, which is developing oral and intravenous antibiotics to treat MRSA, has raised $55M in a Series C funding, the company announced this morning. The funding was led by GP Healthcare Capital, and also included GP TMT Capital, 3E Bioventures Capital, and Delian Capital. Yu Miao of GP Healthcare Capital joins the company's board with the funding. MicuRx is led by Zhengyu Yuan, Ph.D. MicuRx has now raised around $90M in total funding.
posted on Monday, September 26, 2016 (Link to more information)
Related companies:
MicuRx
Related stories:
> MicuRx Finds $25M For Antiobiotic Development
> MicuRx Raises $10M
> EpiBiome Lands $6M For Agricultural Antibiotics Alternatives
> Forest Labs Buys Cerexa For $480M
> Achaogen Takes $56M In Series C Round
silicontap.com Home